Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis

Nature Medicine

Volumn 1, Issue 3, 1995, Pages 256-259

  Palabrica, Theresa M ^a,b   Liu, Alexander C ^c   Aronovitz, Mark J ^a,b   Furie, Bruce ^a,b   Lawn, Richard M ^c   Furie, Barbara C ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; CONTROLLED STUDY; DOSE RESPONSE; FIBRINOLYSIS; LUNG EMBOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STROKE; TRANSGENIC MOUSE;

ANIMAL; APOLIPOPROTEINS; FIBRINOLYSIS; HUMAN; MICE; MICE, TRANSGENIC; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0028951047     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0395-256     Document Type: Article

References (25)

1. Utermann, G. The mysteries of lipoprotein(a). Science 246, 904-910 (1989).
2. Scanu, A.M. & Fless, G.M. Li?o?rotein(a): heterogeneity and biological significance. J. clin. Invest. 85, 1709-1715 (1990).
3. Scanu, A.M., Lawn, R.M. & Berg, K. Lipoprotein(a) and atherosclerosis: Davis Conference Ann. intern. Med. 115, 209-218 (1991).
4. McLean, J.W. et al. Human apolipoprotein(a): cDNA sequence of apolipopro- tein(a) is homologous to plasminogen. Nature 300, 132-139 (1987).
5. Zysow, B.R. & Lawn, R.M. The relationship of lipoprotein(a) to hemostasis. Curr. Opin. Lipidology 4, 484-489 (1993).
6. Lawn, R.M. et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 360, 670-672 (1992).
7. Chiesa, G. et al. Reconstitution of lipoprotein(a) by infusion of human LDL into transgenic mice expressing human apolipoprotein(a). J. biol. Chem. 267, 24369-24374 (1992).
8. Hajjar, K.A., Gavish, D., Breslow, J.L. & Nachman, R.L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339, 303-305(1989).
9. Stassen, J.M., Lijnin, H.R., Kieckens, L. & Collen, D. Small animal thrombosis models for the evaluation of thrombolytic agents. Circulation Suppl IV 83, 65-72 (1991).
10. Carmelliet, P. et al. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis J. clin. Invest 92, 2756-2760 (1993).
11. Miles, L.A., Fless, G.M., Levin, E.G., Scanu, A.M. & Plow, E.F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339, 301-303 (1989).
12. Edelberg, J.M., Gonzalez-Gronow, M. & Pizzo S.V. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 57, 155-162(1990).
13. Loscalzo, J., Weinfeld, M., Fless, G.M. & Scanu, A.M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 10, 240-245 (1990).
14. Liu, J.N., Harpel, P.C., Pannell, R. & Gurewich, V. Lipoprotein (a): A kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator. Biochemistry 32, 9694-9700 (1993).
15. Leerink, C. et al. Lysine-binding heterogeneity of Lp(a): Consequences for fibrin binding and inhibition of plasminogen. Thromb. Haemost. 68. 185-188 (1992).
16. Halvorsen, S., Skjonsberg, O.H., Berg, K., Ruyter, R. & Godal, H.C. Does Lp(a) lipoprotein inhibit the fibrinolytic system? Thromb. Res. 68, 223-232 (1992).
17. Garcia-Frade, L.J. et al. Fibrinolytic parameters and lipoprotein(a) levels in plasma of patients with coronary artery disease. Thromb. Res. 63, 407-418 (1991).
18. Heinrich, H., Sandkamp, M., Kokott, R., Schulte, H. & Assmann, G, Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin. Chem. 37, 1950-1954 (1991).
19. Oshima, S. et al. Transient increase of plasma lipoprotein(a) in patients with unstable angina pectoris. Does lipoprotein(a) alter fibrinolysis. Arte- rioscler. Thromb. 11 1772-1777 (1991).
20. Glueck, CJ. et al. Relationship between lipoprotein(a), lipids, apolipopro- teins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism
21. Scanu, A.M., Praffinger, D., Lee, J.C. & Hinman, J. A single point mutation (Trp72?Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim. Biophys. Acta. 1227, 41-45 (1994).
22. von Hodenberg, E. et al. Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction. Am. J. Cardiol. 67, 1349-1353 (1991).
23. Moliterno, D.J., et al. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation 88, 935-940 (1993).
24. Kudryk, B, Rohoza, A., Ahadi, M., Nechtin, J. & Wiebe, M.E. The specificity of a monoclonal antibody for the NH 2 -terminal region of fibrin. Molec. Immun. 21, 89-94 (1984).
25. Rosenbrough SF et al. Thrombus imaging with indium-111 and iodine-131- labelled fibrin-specific monoclonal antibody and its F(ab)'2 and Fab frag J. nucl. Med. 29, 1212-1222 (1988).